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Abstract
Background: Neuromyelitis optica (NMO) and relapsing-remitting multiple sclerosis (RRMS) are difficult to differentiate
solely on clinical grounds. Optical coherence tomography (OCT) studies investigating retinal changes in both diseases
focused primarily on the retinal nerve fiber layer (RNFL) while rare data are available on deeper intra-retinal layers.
Objective: To detect different patterns of intra-retinal layer alterations in patients with NMO spectrum disorders (NMOSD)
and RRMS with focus on the influence of a previous optic neuritis (ON).
Methods: We applied spectral-domain OCT in eyes of NMOSD patients and compared them to matched RRMS patients and
healthy controls (HC). Semi-automatic intra-retinal layer segmentation was used to quantify intra-retinal layer thicknesses. In
a subgroup low contrast visual acuity (LCVA) was assessed.
Results: NMOSD-, MS- and HC-groups, each comprising 17 subjects, were included in analysis. RNFL thickness was more
severely reduced in NMOSD compared to MS following ON. In MS-ON eyes, RNFL thinning showed a clear temporal
preponderance, whereas in NMOSD-ON eyes RNFL was more evenly reduced, resulting in a significantly lower ratio of the
nasal versus temporal RNFL thickness. In comparison to HC, ganglion cell layer thickness was stronger reduced in NMOSD-
ON than in MS-ON, accompanied by a more severe impairment of LCVA. The inner nuclear layer and the outer retinal layers
were thicker in NMOSD-ON patients compared to NMOSD without ON and HC eyes while these differences were primarily
driven by microcystic macular edema.
Conclusion: Our study supports previous findings that ON in NMOSD leads to more pronounced retinal thinning and visual
function impairment than in RRMS. The different retinal damage patterns in NMOSD versus RRMS support the current
notion of distinct pathomechanisms of both conditions. However, OCT is still insufficient to help with the clinically relevant
differentiation of both conditions in an individual patient.
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Introduction
Neuromyelitis optica (NMO) is a rare autoimmune central
nervous system (CNS) condition that predominantly affects the
optic nerves and the spinal cord [1,2]. While NMO had previously
been regarded as variant of multiple sclerosis (MS), the recent
detection of a highly specific serum biomarker for NMO,
antibodies to the most abundant astrocytic CNS water channel
aquaporin-4 (AQP4), as well as histopathological data has made
clear that NMO is a condition distinct from MS [1,3–7].
An early and accurate diagnosis of NMO and distinction from
MS is crucial as prognosis is usually worse than in MS and
treatment options for both diseases differ considerably [8].
Although the broad availability of commercial testing for
antibodies to AQP4 has facilitated differentiation of NMO from
MS, a correct diagnosis remains challenging, in particular in those
NMO patients who test negative for AQP4 antibodies. Thus, a
considerable number of patients are still misdiagnosed with MS
[1,9].
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Optical coherence tomography (OCT) is a non-invasive
interferometry technique that has been used to measure retinal
nerve fiber layer (RNFL) thickness, total macular volume
(TMV) and ganglion cell layer (GCL) thickness in MS and
other neurological diseases [10–14]. In MS, numerous studies
have consistently shown reduced RNFL, TMV, and GCL across
disease subtypes and in both eyes with and without prior history
of optic neuritis (ON) [14–22]. Moreover, measures of retinal
neuroaxonal damage were found to correlate with brain atrophy
in MS [23–27].
Previous OCT studies have shown that ON in NMO causes
more severe neuronal damage and greater thinning of the RNFL
than ON in MS [28–34], which is in line with the clinical
experience that visual acuity in NMO is usually more severely
affected and visual outcome poorer than in MS [2,8]. Moreover,
and again in contrast to MS, increase in retinal damage as
measured by OCT seems to be exclusively linked to clinical ON
attacks in NMO while progressive retinal neuroaxonal damage
independent of clinically apparent ON as in MS is rare in NMO
[35].
In NMO, there are only few studies on retinal OCT data
acquired with the high-resolution spectral-domain (SD) technology
[36–39] most of which did not present data on segmentation of
deeper retinal layers. The goal of our study was to analyze OCT
measures from all retinal layers in patients with NMO or MS
rigorously matched for history of ON and in healthy controls
(HC), and to relate these measures to visual functions. We were
interested whether the more severe retinal affection in NMO-ON
as compared to MS-ON described in earlier OCT studies would
also be detectable in deeper retinal layers and whether damage
patterns differ between both conditions. If so, OCT could be an
additional tool to aid in the clinically challenging differential
diagnosis of MS and NMO.
Materials and Methods
Study Participants
Seventeen patients with NMO and NMO spectrum disorder
(NMOSD) [5] were prospectively recruited from the outpatient
clinics of the NeuroCure Clinical Research Center and of the
Department of Neurology, Charite´ Universitaetsmedizin Berlin.
Thirteen patients fulfilled the 2006 diagnostic criteria for NMO,
and 4 had NMOSD (3 with longitudinally extensive transverse
myelitis (LETM), 1 with recurrent optic neuritis) with AQP4
antibodies [40]. Ninety four percent (16/17) were seropositive for
AQP4 antibodies [41–43]. HC and relapsing-remitting MS
(RRMS) patients according to the 2010 revised McDonald criteria
[44] were matched from the center’s research database according
to age and gender. NMOSD and MS patients were additionally
matched eye-wise for history of ON, determined by medical
record review. Exclusion criteria were eye or retina diseases other
than ON, refractive error greater than 66 dpt and acute ON or
treatment with corticosteroids within three months prior to OCT
examination.
Ethics Statement
The study was approved by the local ethics committee at the
Charite´ - Universita¨tsmedizin Berlin and was conducted following
the Declaration of Helsinki in its currently applicable version, the
guidelines of the International Conference on Harmonisation of
Good Clinical Practice and the applicable German laws. All
participants gave informed written consent.
Optical Coherence Tomography
OCT examination was performed with the Spectralis SD-OCT
(Heidelberg Engineering, Heidelberg, Germany) without pupil
dilatation. RNFL thickness was measured using a 3.4 mm circular
scan around the optic nerve head with the device’s standard
protocol and segmentation algorithm with activated eye tracker.
Ring scan parameters included into analysis were average
peripapillary RNFL (pRNFL), quadrant RNFL thicknesses
(figure 1A), and nasal to temporal RNFL ratio (N/T ratio). The
TMV was assessed by a custom scan that uses 61 vertical B-scans
(each with 768 A-Scans, ART = 13 frames) with a scanning angle
of 30u625u focusing on the fovea. All scans passed published
quality control criteria [45].
Intra-retinal Layer Segmentation
Heidelberg Engineering provided a beta software version with a
multilayer segmentation algorithm for macular volume scans
(Spectralis software version 5.5.0.5, Eye Explorer Software
1.7.0.0). To analyze the inner retinal layers of macular volume
scans a subset of B-scans were segmented and manually corrected
by an experienced rater in a blinded fashion. The multilayer
analysis was performed on the central B-scan through the fovea
and on three B-scans each in nasal and temporal direction. Every
fourth B-scan from the original volume scan was used resulting in
a distance between analyzed B-scans of approximately 500 mm.
The mean thickness was calculated for the following retinal layers
(figure 1C): macular RNFL (mRNFL), GCL, inner plexiform layer
(IPL) and inner nuclear layer (INL). The outer retinal layers
(ORL), including the outer plexiform layer (OPL), outer nuclear
layer (ONL) and inner photoreceptor layer segments (IS), were
analyzed in combination. We analyzed thickness data within a box
centered around the fovea and excluding the superior and inferior
parts of the scan prone to vessel artifacts as well as the central
fovea (Figure 1B). Microcystic macular edema (MME) was defined
as presence of cystic lesions located in the inner nuclear layer on at
least two adjacent B-scans [46].
Visual Function Testing
High contrast visual acuity (VA) of both eyes was assessed
monocularly for both eyes using ETDRS charts integrated in the
Optec 6500 P system (Stereo Optical Co, Inc, Illinois, USA) on
the same day as OCT examination in all groups. The resulting
value was converted into Snellen equivalents. Low contrast visual
acuity (LCVA) was assessed using Functional Acuity Contrast
Testing with the Optec 6500 P system. Both eyes were tested in
monocular mode following the standards published by the
American National Standards Institute with best correction under
photopic (‘‘day light’’ with target luminance value of 85 cd/m2)
conditions without glare as previously described in detail [47].
Briefly, the linear sine-wave grating charts tested for five spatial
frequencies, each with nine levels of contrast. Contrast sensitivity
was then recorded as the lowest contrast level achieved by a
patient for each spatial frequency. From the five spatial frequency
measurements, a function over all measurements was calculated
using a least square curve fit and the area under the curve was
then established as the area under this function between the lowest
and highest spatial frequency, providing a summary expression
over all measurements.
Statistical Analysis
Cohort differences were analyzed using Kruskal Wallis test for
age of all groups and Mann-Whitney-U tests (MWU) for time since
diagnosis and time since last ON of the NMOSD and the MS
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group. To investigate differences in OCT measures between the
different cohorts and between ON and NON eyes, generalized
estimation equation models (GEE) with working correlation
matrix ‘exchangeable’ were used accounting for within-patient
inter-eye dependencies. In all GEE models, diagnosis was used as
independent variables and OCT parameters as dependent
variables. To account even for potential effects of demographic
variables we also corrected for age and gender. The monocular
association between GCL and visual function was tested using
linear regression models (LR) with GCL as independent and visual
function as dependent variable with no further covariates. For
subgroup analyses (ON or NON eyes) only the respectively
matched HC eyes were included in the analyses, resulting in
different, but exactly eye-wise matched cohorts.
All statistical analyses were performed with SPSS 20 (IBM
SPSS, NY, USA), all graphical figures were created using R (basic
R version 2.15.2 including the ggplot2 package). Statistical
significance was achieved at p,0.05. All tests should be
understood and interpreted as constituting exploratory data
analysis in such way that no previous power calculation or
adjustments for multiple testing were made.
Results
The demographic data of the study participants is summarized
in table 1. Complete data was available from all patients for OCT
and high contrast VA. In addition, LCVA was available from 13
NMOSD patients. To avoid inclusion bias only the LCVA results
of the respectively matching 13 MS patients were included. Six
NMOSD and 6 MS patients had a history of ON for both eyes,
eight patients in each group had a unilateral ON and three
patients had LETM without history of ON. There were no
significant differences in age between the cohorts (Kruskal Wallis
test, p = 0.893), yet disease duration was significantly longer in the
MS group compared to the NMOSD group (MWU, p = 0.026).
There was no significant difference in time since last ON between
MS and NMOSD patients’ eyes with a history of ON (MWU,
p = 0.181).
OCT Measures in NMOSD and MS Eyes with ON
mRNFL, GCL and IPL were significantly reduced in NMOSD-
ON eyes compared to HC (table 2). On the contrary, INL
thickness and the outer retinal layers were significantly increased
in NMOSD-ON eyes when compared to HC eyes. NMOSD-ON
eyes also showed a significantly more pronounced mRNFL, GCL
and IPL thinning than MS-ON eyes while slight differences in INL
and the outer retinal layers were not significant (sample cases in
figure 2).
ON in NMOSD eyes resulted in stronger visual function
impairment than ON in MS eyes: High contrast VA was
significantly lower with NMOSD-ON eyes (Mean 6 SD:
0.4860.51) compared to MS-ON eyes (0.9160.37, GEE:
B =20.4, SE = 0.1, p = 0.002). Likewise, low contrast LCVA
was reduced with NMOSD-ON eyes (1.0360.89) when compared
to MS-ON eyes (1.5560.50, GEE: B =20.5, SE = 0.2, p = 0.024).
GCL thickness was related to VA in NMOSD-ON eyes (LR:
R2 = 0.441, p = 0.001) better than in MS-ON eyes (LR:
R2 = 0.242, p = 0.028) (figure 3A). The same held true for LCVA
in NMOSD-ON (LR: R2 = 0.467, p = 0.002) versus MS-ON eyes
(LR: R2 = 0.143, p = 0.135) (figure 3B).
Different Affection of Quadrant pRNFL in NMOSD and MS
after ON
pRNFL thickness was significantly decreased in eyes from
patients with either of the two disorders compared to HC, with
NMOSD-ON eyes being significantly more affected than MS-ON
eyes in all quadrants (table 2). As it is a long-standing clinical
experience that optic disc pallor and optic atrophy in MS-ON eyes
may exhibit a temporal preponderance and as also histopatho-
logical and OCT works have shown particular damage to
temporal axons [48–50], we were curious whether a predilection
of the temporal quadrant of pRNFL would also be detectable in
NMOSD. While pRNFL was indeed primarily reduced in the
temporal quadrant in MS-ON eyes, pRNFL in NMOSD-ON eyes
was more broadly reduced with thinning involving other
quadrants. We used the ratio of nasal versus temporal RNFL
thickness (N/T ratio) for comparing quadrant-wise thinning in the
groups NMOSD-ON and MS-ON. N/T ratio was significantly
lower in NMOSD-ON than in MS-ON (0.9360.35 vs.
1.3660.43; GEE: B =20.38, SE = 0.13, p = 0.004), meaning that
in relation to the temporal quadrant, the nasal quadrant was much
stronger affected in NMOSD than in MS. These results are
emphasized by the representative pRNFL quadrant thickness
values in figure 2.
Figure 1. Sample OCT measurement and segmentation. A) Sample scanning laser ophthalmoscopy image showing the peripapillary ring-scan
for retinal nerve fiber layer analysis. Nasal and temporal quadrants were analyzed separately B) Sample scanning laser ophthalmoscopy image
showing the B-scans included in the segmentation procedure (green and blue) and the area included into analysis (blue only). C) Sample macular
scan showing the segmentation lines and intra-retinal layer layout. Red segmentation lines provided by the software define the macular retinal nerve
fiber layer (mRNFL), the ganglion cell layer (GCL), the inner plexiform layer (IPL), the inner nuclear layer (INL), the outer plexiform layer (OPL), the outer
nuclear layer (ONL), and inner segments of the photoreceptor layer (IS). OPL, ONL and IS were analyzed combined as outer retinal layers (ORL). D)
Sample B-scan of an NMOSD patient with microcystic macular edema (MME).
doi:10.1371/journal.pone.0066151.g001
Table 1. Demographic and clinical overview.
NMOSD RRMS HC
Subjects n 17 17 17
Gender Female 16 16 16
Male 1 1 1
Age [years] mean 6 SD 40.8612.3 41.2612.7 41.4612.4
Min–Max 19–63 20–64 21–66
Time since diagnosis
[months]
Mean 6 SD 44.3638.2 93.7665.8 n/a
Min–Max 3–129 3–240 n/a
AQP4-Ig positive n 16 n/a n/a
Eyes n 34 34 34
Eyes with a history
of ON
n 20 20 n/a
Time since last ON
[months]
Mean 6 SD 45641 65646 n/a
Min–Max 3–130 3–160 n/a
Abbreviations: NMOSD: neuromyelitis optica spectrum disorders; RRMS:
relapsing-remitting multiple sclerosis; HC: healthy controls; AQP4-Ig: aquaporin
4 antibodies; ON: optic neuritis, n/a = not applicable (the resp. data did not
apply to this group).
doi:10.1371/journal.pone.0066151.t001
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To further analyze the potential value for differential diagnosis
we calculated ROC curves. Here, pRNFL showed an AUC of
0.835 (corresponding to 60% sensitivity at 90% specificity to
identify an NMOSD related optic neuritis by this measure) and N/
T ratio an AUC of 0.775 (corresponding to 50% sensitivity at 90%
specificity). These values should be interpreted with caution due to
the low number of cases and the exploratory nature of the analysis
and are only given for comparison of our results to other studies.
To investigate whether the N/T ration may be NMOSD
specific or whether a severe ON might lead in general to a broader
loss of pRNFL, we selected 20 additional eyes with a history of ON
from 17 RRMS patients presenting with very thin pRNFL values
from our OCT database. In order to analyze MS patients with the
most severe pRNFL reduction, we simply chose those 17 RRMS
patients in our database with the lowest pRNFL values without
any further criteria or a specific cutoff. Despite these eyes
(59.266.0 mm) showing a comparable pRNFL thickness with
NMOSD-ON eyes (58.5621.2 mm, p = 0.984), the N/T ratio in
these eyes (1.4760.42) was in the range of the originally matched
MS-ON eyes (GEE: p = 0.361) and statistically highly significantly
different from NMOSD-ON eyes (GEE: B =20.53, SE = 0.13,
p,0.001), further supporting the evidence for a different damage
pattern in NMOSD compared to MS.
None of the MS-ON eyes showed a pRNFL below 46.6 mm
whereas 9 NMOSD-ON eyes (45%) had a pRNFL below this
value. No MS-ON eyes showed an N/T ratio below 0.61, while 5
NMOSD-ON eyes (25%) were below this limit. Four NMOSD-
ON eyes (20%) showed both pRNFL and N/T ratio below these
cut-off values.
Role of Microcystic Macular Edema (MME)
Four eyes from three NMOSD patients (75%) were affected by
MME (figure 1D). All patients with MME reported a previous ON
in the respective eye. In contrast, no MS patient or HC was
affected by MME. Eyes with MME (MME+) in NMOSD patients
showed severely reduced RNFL, GCL, and IPL, but increased
INL and outer layers in comparison to NMOSD-ON eyes without
MME (MME-) (figure 4, MME+ in red).
All MME+ eyes performed very poorly in high and low visual
acuity testing with three eyes being legally blind. VA was
significantly lower in MME+ eyes (Mean 6 SD 0.1260.19) than
in MME- eyes (0.5760.53, GEE: B = 0.609, SE = 0.123, p,0.001)
and LCVA was reduced in MME+ eyes (0.1660.33) when
compared to MME- eyes (1.3060.83, GEE: B = 1.237,
SE = 0.163, p,0.001).
To test whether the above reported INL and outer layer
thickening in NMOSD-ON eyes over HC eyes was a result of
MME, we performed all corresponding group comparisons also
under exclusion of MME affected eyes and their respective
controls. Comparing these cohorts, no significant increase of INL
(p = 0.363) and outer layers (p = 0.336) was detected in NMOSD
eyes anymore. pRNFL (B =238.6, SE = 5.8) and the inner retinal
layers mRNFL (B =26.9; SE = 1.7), GCL (B =215.2, SE = 2.6)
and IPL (B =28.7, SE = 2.0) were still significantly decreased in
comparison to HC eyes (all p,0.001). These layers were also
reduced in NMOSD-ON eyes compared to MS-ON eyes
(mRNFL: B = - 3.7, SE = 1.5, p = 0.015; GCL: B =26.1,
SE = 2.2, p = 0.007; IPL: B =27.0, SE = 2.1, p = 0.001).
NMOSD vs. MS Eyes without Previous Optic Neuritis
Finally, we investigated whether NMOSD patient’s eyes without
any history of ON showed retinal changes in comparison to
healthy controls. Detailed results comparing retinal measures of
NMOSD-NON with eyes from HC are given in table 3. In
summary, NMOSD-NON eyes did not differ significantly from
HC eyes in any of the OCT layer measures. For comparison with
MS, we additionally compared MS-NON eyes with HC. MS-
NON eyes showed reduced thickness in macular RNFL and GCL
and a slight non-significant thickening of INL and outer layers.
Table 2. Retinal morphology in eyes after ON.
NMOSD-ON MS-ON (vs. NMOSD-ON) Matched HC (vs. NMOSD-ON)
Mean ± SD Min–Max Mean ± SD Min–Max B (SE) p Mean ± SD Min–Max B (SE) p
Average pRNFL (mm) 58.5621.2 28.0–93.4 85.3613.3 62.3–105.2 226.7 (5.3) ,0.001 100.1610.8 80.7–122.3 41.5 (5.1) ,0.001
inferior pRNFL (mm) 79.18629.3 36.1–134.9 115.4–17.9 81.1–144.9 235.9 (7.1) ,0.001 131.0614.9 97.4–155.0 251.6 (7.1) ,0.001
superior pRNFL (mm) 73.6626.1 25.2–124.9 105.7618.4 71.8–138.0 231.9 (7.1) ,0.001 120.6616.0 94.0–157.1 246.7 (7.2) ,0.001
nasal pRNFL (mm) 38.6619.5 11.3–87.8 67.7615.1 37.8–89.0 229.1 (5.4) ,0.001 76.5619.7 35.5–105.0 237.8 (5.9) ,0.001
temporal pRNFL (mm) 42.4.616.6 17.9–78.7 52.5614.7 35.1–89.8 29.9 (4.6) 0.031 72.2610.4 53.2–95.6 229.7 (4.3) ,0.001
TMV (mm3) 7.9660.47 7.04–8.67 8.3160.48 7.44–9.02 20.34
(0.14)
0.019 8.5260.53 7.75–9.38 20.56
(0.15)
,0.001
mRNFL (mm) 25.666.2 13.2–35.5 29.464.0 22.8–37.5 23.7 (1.5) 0.015 33.462.3 29.5–36.4 27.8 (1.4) ,0.001
GCL (mm) 3068.5 9.1–46.3 36.165.8 27.1–44.4 26.1 (2.2) 0.007 45.565.1 37.8–56.3 215.4 (2.1) ,0.001
IPL (mm) 26.0–7.0 16.4–38.2 33.167.0 22.5–44.8 27.0 (2.1) ,0.001 35.965.2 27.6–45.5 29.8 (1.9) ,0.001
INL (mm) 41.565.3 34.5–54.1 39.363.1 33.4–44.6 0.075 38.963.1 33.2–45.9 2.6 (1.3) 0.045
Outer layers (mm) 114.666.6 96.7–128.5 113.569.6 102.0–134.8 0.683 110.366.94 99.2–122.9 4.2 (2.0) 0.035
Results of retinal OCT outcomes of NMOSD and MS patients’ eyes after optic neuritis and healthy controls; GEE results showing the differences between NMOSD-ON and
MS-ON and NMOSD-ON to healthy controls.
Abbreviations: NMOSD: neuromyelitis optica spectrum disorder; MS: multiple sclerosis; NON: eyes without history of optic neuritis; HC: healthy controls; OCT: optical
coherence tomography; p/mRNFL: peripapillary and macular retinal nerve fiber layer; TMV: total macular volume; GCL: ganglion cell layer; IPL: inner plexiform layer; INL:
inner nuclear layer; SD: standard deviation; Min: minimum; Max: maximum; B: coefficient estimate from generalized estimating equation models (GEE), SE: standard error
from GEE coefficient estimates.
doi:10.1371/journal.pone.0066151.t002
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Discussion
In this study we used SD-OCT with intra-retinal segmentation
to investigate retinal layer changes in 17 NMOSD patients in
comparison to matched RRMS patients and HC. In line with
clinical data and previous OCT studies [32,36,37] we show that
neuroaxonal retinal damage displayed by thinning of the
peripapillary and macular RNFL and of the GCL is more severe
in ON eyes from patients with NMOSD than in ON eyes from
patients with MS. This is paralleled by poorer visual functions as
assessed by high and low contrast visual acuity. Interestingly, the
association of structural retinal damage and impairment of visual
function was more apparent in NMOSD-ON eyes than in MS-
ON eyes: GCL thickness was a much stronger predictor of both
ETDRS visual acuity and LCVA measured by Functional Acuity
Contrast Testing in NMOSD than in MS. Half of NMOSD-ON
eyes had pRNFL values below 46.6 mm versus none of the MS-
ON eyes, and the mean pRNFL difference between both groups
was 27 mm. This difference is in striking accordance with values
reported by two previous seminal studies in NMO using the older
time domain OCT technology [29,30]. The stronger association
between morphology and visual function in NMOSD-ON eyes
that tend to have lower axonal and neuronal OCT measures may
suggest that below a certain threshold of neuroaxonal loss retinal
neurons and axons are no longer able to sufficiently maintain
visual function. Other studies in patients with ON or NMO
further underscore the assumption of a threshold RNFL thickness,
below which visual acuity becomes very poor [30,51,52]. This has
Figure 2. Sample patient data from NMOSD and MS eyes. A) Peripapillary retinal nerve fiber layer (pRNFL) thickness data (in mm) for average
RNFL (G) and sectors (nasal-superior quadrant (NS), temporal-superior (TS), temporal, temporal-inferior (TI), nasal-inferior (NI) and nasal (N)) for a
multiple sclerosis (MS) patient’s eye with a previous optic neuritis (ON) (left), a neuromyelitis optica spectrum disorder (NMOSD) patient’s eye with a
previous ON without microcystic macular edema (MME) (center), and an NMOSD patient’s eye with previous ON and MME (right). Background colors
describe the comparison to a healthy reference group from the device’s database. B) and C) Thickness maps of the retinal ganglion cell layer (GCL, B)
and inner nuclear layer (INL, C) respective to the patients’ data from A).
doi:10.1371/journal.pone.0066151.g002
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important implications as early and effective therapeutic interven-
tions following ON should aim to prevent substantial retinal
damage and thus poor visual function which negatively influences
the patient’s quality of life [53,54]. Several recent studies have
indeed shown that therapeutic interventions with corticosteroids,
plasma exchange or erythropoietin after an ON attack may help
preserve retinal axons and this effect can be monitored by OCT
[28,55,56]. This further supports the argument of some authors
that strict immunosuppression is mandatory in NMO [57].
Importantly, non-affected eyes in NMOSD had normal visual
function and preserved retinal layers.
Our results support previous findings on a distinct distribution
of RNFL thinning across quadrants in NMOSD-ON eyes versus
MS-ON eyes. Consistent with Naismith et al. [29] and Monteiro
et al. [32], the temporal preponderance of RNFL damage typical
for MS was not detectable in NMOSD eyes. Here, other
quadrants were as well severely affected, resulting in a significantly
lower nasal to temporal pRNFL ratio in NMOSD versus MS.
However, given the limited sample size in our and the two
previous cohorts and the substantial overlap of data between MS
and NMOSD, the N/T ratio is currently of limited value to
differentiate between a NMOSD-ON and a MS-ON eye on an
individual level. The pathophysiological aspects, however, deserve
discussion. The temporal quadrant of the RNFL contains the
papillo-macular bundle, which is built by parvocellular axons that
consist of smaller, thinly myelinated fibers with rapid firing rates.
Interestingly, several diseases besides MS show a predominant
impairment of these parvocellular axons such as Leber’s hereditary
optic neuropathy, OPA1 related dominant optic nerve atrophy,
and spinocerebellar ataxia type 1 [58]. All these diseases share a
presumed insult to mitochondria as one key event in the disease
process. Owing to their small volume and fast firing rates,
parvocellular axons may be more vulnerable to energy depletion
resulting from impaired mitochondrial function [59].
Support for this assumption stems from an autopsy study by
Evangelou et al. who demonstrated a selective vulnerability to
injury of parvocellular axons and neurons in the anterior optic
pathway in MS [60]. In contrast, the more even distribution of
retinal damage in NMOSD-ON eyes as compared to MS-ON
may indicate that damage to parvocellular axons is not a key
feature in NMO but other mechanisms are more important.
In line with some previous reports [30,33], NMOSD-NON eyes
exhibited no apparent retinal damage as all OCT measures were
not different from controls. This is concordant with the notion that
retinal damage in NMO is linked to clinically manifest ON attacks
and does not occur progressively or as a consequence of subclinical
optic neuropathy as is the case in MS. Accordingly, a secondary
progressive course has been rarely described in NMO [35]. In
contrast to our and other groups Syc et al. and Sotirchos et al.
reported GCL plus IPL thinning also in NMOSD eyes without
history of ON [36,39]. As the authors acknowledge, subclinical
disease activity in NMOSD is not a widely appreciated phenom-
Figure 3. Correlation between visual function and retinal
morphology. Scatterplots illustrating relations of ganglion cell
thickness of neuromyelitis optica spectrum disorder (NMOSD) and
multiple sclerosis (MS) patients’ eyes with a previous optic neuritis to A)
high contrast visual acuity (determined by ETDRS charts) and B) low
contrast visual acuity determined by functional acuity contrast testing.
doi:10.1371/journal.pone.0066151.g003
Figure 4. Intra-retinal layer thickness in NMOSD-ON eyes with
and without microcystic macular edema. Layer thicknesses for the
macular retinal nerve fiber layer (mRNFL), ganglion cell layer (GCL),
inner plexiform layer (IPL), inner nuclear layer (INL) and the combined
outer retinal layers for NMOSD-ON eyes with (MME+, in red) and
without (MME-, in blue) microcystic macular edema and healthy
controls eyes (HC, in green). Outer retinal layers include outer plexiform
layer, outer nuclear layer and inner photoreceptor layer segments.
doi:10.1371/journal.pone.0066151.g004
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enon. These discrepant findings from studies using high resolution
SD-OCT with intra-retinal segmentation can currently not be
resolved; the use of two different OCT devices and segmentation
techniques and the relatively low number of NMOSD-NON eyes
in both studies with an inherent risk for statistical errors may have
played a role. However, the topic deserves to be addressed in
larger studies, as the finding of subclinical optic neuropathy in
NMO would question our current pathophysiological understand-
ing of NMO.
Of note are our findings of MME in four NMOSD-ON eyes.
MME in these few eyes was responsible for the apparent
thickening of the INL in NMOSD-ON eyes versus HC that was
no longer present when we excluded these MME eyes from group
comparisons. MME has recently been described by Gelfand and
colleagues in 15 of 318 MS patients [46]. MME was associated
with disease severity, reduced visual acuity and RNFL thinning.
Moreover, MME was predominantly located in the INL and was
more prevalent in eyes with prior symptomatic ON. However, the
question as to whether MME is specific for MS or may also occur
in other conditions with optic nerve involvement remains to be
answered [61,62].
In line with this, both Sotirchos et al. and Gelfand et al. [38,39]
reported MME exclusively in NMO eyes affected by ON as was
the case in our study. Moreover, all three works consistently found
that MME NMO eyes exhibited more severe structural retinal
damage and more profoundly impaired visual function than non
MME NMO eyes. In this regard, the recent proposal by Balk and
colleagues that MME may be linked to Mueller cell pathology is
intriguing and warrants further investigation [61]. In NMO one
could hypothesize targeting of Mueller cells which are AQP4-
containing retinal astrocytes of the retina by AQP4 autoantibodies.
In AQP4 knock-out mice, electroretinograms have suggested that
lack of AQP4 mildly impairs retinal function, presumably by
altered Mueller cell fluid balance [63]. However, it remains to be
investigated if AQP4 antibodies that have been shown to be
pathogenic in NMO [64], may have access to the retina via a leaky
blood-retina barrier and thus can target retinal Mueller cells. This
could be another cause of retinal damage beyond a retrograde
degeneration of ganglion cells following an attack to axons in the
optic nerve [36].
In light of recent studies that have shown a detrimental effect of
some MS disease-modifying drugs in NMO [65–73], the
possibility of using OCT for a more accurate diagnosis of NMO
and for a correct differential diagnosis versus MS would be
desirable, especially in AQP4 antibody negative patients. Howev-
er, despite some distinct features of retinal damage we and others
have identified by OCT group comparisons, the discriminatory
capacity of OCT for a reliable differential diagnosis of the
individual patient is still insufficient to be used in clinical routine.
Moreover, it is a limitation of our and most previous studies that
the sample size of the NMO cohorts were relatively small owing to
the rarity of NMO, thus results are prone to statistical errors.
Further technical advances in OCT technology with respect to
data acquisition and post-processing will hopefully improve the
utility of the technique for clinically routine in the near future.
Acknowledgments
We thank Cynthia Kraut for excellent technical support.
Author Contributions
Conceived and designed the experiments: HZ AP AUB FP. Performed the
experiments: ES HZ FK FB. Analyzed the data: HZ TO EMK AUB NB.
Contributed reagents/materials/analysis tools: BW SJ KR AUB FP. Wrote
the paper: ES HZ TO AUB FP.
Table 3. Retinal morphology in eyes without previous ON.
Matched HC NMOSD-NON (vs. HC) MS-NON (vs. HC)
Mean ± SD Min–Max Mean ± SD Min–Max p Mean ± SD Min–Max B (SE) p
Average
pRNFL
(mm)
97.0612.1 80.4–120.8 99.567.5 88.9–113.7 0.5 92.568.9 71.5–100.9 0.69
TMV
(mm3)
8.5260.53 7.75–9.38 8.4560.34 8.02–9.16 0.355 8.5960.28 8.21–9.13 0.086
mRNFL
(mm)
34.462.9 26.6–40.3 34.862.0 32.4–38.4 0.61 31.762.9 27.0–39.4 22.4 (1.1) 0.025
GCL (mm) 44.964.2 37.5–52.8 43.362.0 36.6–50.5 0.293 41.365.3 31.5–49.0 23.6 (1.7) 0.039
IPL (mm) 35.863.8 30.4–44.3 35.364.4 26.9–40.9 0.69 34.463.5 29.0–39.0 0.266
INL (mm) 39.162.4 33.8–43.8 38.463.4 32.3–46.7 0.507 40.562.2 36.3–43.7 0.095
Outer
layers
(mm)
110.566.5 98.4–122.9 109.365.4 94.7–116.3 0.52 113.365.4 103.1–123.9 0.201
Results of retinal OCT outcomes of NMOSD and MS patients’ eyes without history of optic neuritis and healthy controls; GEE results showing the differences between
NMOSD-NON and MS-NON to healthy controls. Outer retinal layers include outer plexiform layer, outer nuclear layer and inner photoreceptor layer segments.
Abbreviations: NMOSD: neuromyelitis optica spectrum disorder; MS: multiple sclerosis; NON: eyes without history of optic neuritis; HC: healthy controls; OCT: optical
coherence tomography; p/mRNFL: peripapillary and macular retinal nerve fiber layer; TMV: total macular volume; GCL: ganglion cell layer; IPL: inner plexiform layer; INL:
inner nuclear layer; SD: standard deviation; Min: minimum; Max: maximum; B: coefficient estimate from generalized estimating equation models (GEE), SE: standard error
from GEE coefficient estimates.
doi:10.1371/journal.pone.0066151.t003
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